Welcome to our dedicated page for ASP Isotopes SEC filings (Ticker: ASPI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ASP Isotopes's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ASP Isotopes's regulatory disclosures and financial reporting.
ASP Isotopes’ subsidiary Quantum Leap Energy has deepened its collaboration with the South African Nuclear Energy Corporation (Necsa) by signing a Pre-Implementation Services Contract for a planned High Assay Low Enriched Uranium (HALEU) enrichment facility at Necsa’s Pelindaba site.
Under the agreement, Necsa will provide facilities, infrastructure, utilities and services to support the siting, design, construction, commissioning and operation of the enrichment facility. A joint committee with representatives from both parties will oversee implementation, aiming to bring QLE’s HALEU production capabilities to market readiness.
The partnership combines QLE’s proprietary Aerodynamic Separation Process and Quantum Enrichment technologies with Necsa’s established nuclear infrastructure and global networks. It targets growing demand for HALEU, a key fuel for small modular and other advanced reactors, as advanced nuclear projects scale to serve data centers and industrial electrification.
ASP Isotopes Inc., through its wholly owned subsidiary Quantum Leap Energy (QLE), has created a Strategic Advisory Board to support its plans in the nuclear fuel sector and appointed two initial members, nuclear engineering academic leader Mary Lou Dunzik-Gougar and advanced materials executive Kevin Kramer.
The board is expected to guide QLE as it develops proprietary technologies to address inefficiencies, environmental concerns, and supply chain vulnerabilities across the nuclear fuel cycle, including front-end enrichment activities and back-end waste treatment technologies for advanced reactors, fusion systems, and the existing nuclear fleet.
ASP Isotopes Inc. received an updated ownership report on its common stock from shareholder Paul E. Mann. Mann reported beneficial ownership of 7,759,538 shares of common stock, representing 7.0% of the class, as of 12/31/2025. He has sole voting and dispositive power over all reported shares, with no shared voting or investment power disclosed.
ASP Isotopes, through its wholly owned subsidiary Quantum Leap Energy (QLE), plans to establish QLE’s new global corporate headquarters in Austin, Texas. The move is intended to strengthen its Texas presence and position the development-stage nuclear fuels company closer to its U.S. customer base.
QLE also plans a significant operational presence in Texas, working with Fermi America under an existing memorandum of understanding to pursue a joint venture for a high-assay low-enriched uranium enrichment research and commercial production facility linked to Fermi America’s hypergrid campus in Amarillo. This would be developed alongside ASP Isotopes’ planned commercial facility for stable isotopes and advanced nuclear materials.
The announcement highlights Texas’ supportive regulatory and business environment for nuclear power and notes U.S. Department of Energy estimates that domestic demand for HALEU could reach 50 metric tons per year by 2035 and 500 metric tons per year by 2050, underscoring the potential market for advanced nuclear fuels.
BNP Paribas Asset Management UK Ltd has filed an amended Schedule 13G reporting beneficial ownership of 944,326 shares of ASP Isotopes Inc. common stock, representing 0.9% of the outstanding class as of December 31, 2025. The firm reports sole voting and dispositive power over all of these shares and confirms they are held in the ordinary course of business, not to change or influence control of ASP Isotopes.
ASP Isotopes Inc. agreed to invest in biotechnology company Opeongo by purchasing 4,356,918 shares of Opeongo’s Series Seed-1 Preferred Stock at an original purchase price of $2.2952 per share. The preferred stock is convertible into Opeongo common stock and carries anti-dilution protections, voting rights, and the ability for Series Seed-1 holders to elect a dedicated director while enough shares remain outstanding.
ASP Isotopes and other investors also received veto rights over certain major Opeongo corporate actions and contractual protections through investors’ rights, right of first refusal and co-sale, and voting agreements. Within thirty days after January 26, 2026, ASP Isotopes and Opeongo are obligated to negotiate a draft supply agreement giving ASP Isotopes a right of first offer for medical isotope supply tied to Opeongo’s future pharmaceutical products.
The Vanguard Group reported a passive ownership stake in ASP Isotopes Inc common stock on a Schedule 13G. Vanguard beneficially owns 6,406,244 shares, representing 5.77% of the outstanding common stock. It has shared voting power over 873,110 shares and shared dispositive power over all 6,406,244 shares, with no sole voting or dispositive authority.
Vanguard states the shares are held in the ordinary course of business, not to change or influence control of ASP Isotopes. Following an internal realignment on January 12, 2026, certain Vanguard subsidiaries are expected to report beneficial ownership separately while pursuing the same investment strategies as before.
ASP Isotopes Inc. filed a current report to share that it issued a press release providing a production update on the Helium Project of Renergen Limited. The press release, dated January 29, 2026, is attached as Exhibit 99.1 and is incorporated by reference into the report.
The information is furnished under Regulation FD, meaning it is intended to ensure broad, non-selective disclosure. The company also notes that the press release contains forward-looking statements covered by the Private Securities Litigation Reform Act safe harbor provisions.
Encompass Capital Advisors LLC filed a Schedule 13G reporting a significant passive ownership stake in ASP Isotopes Inc. common stock. The firm and its managing member, Todd J. Kantor, together report beneficial ownership of 6,413,362 shares, representing 5.13% of ASP Isotopes’ outstanding common stock as of the event date 01/16/2026.
Both Encompass and Kantor report shared voting and dispositive power over all 6,413,362 shares and no sole power to vote or dispose of any shares. They certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of ASP Isotopes, indicating a passive investment intent. A joint filing agreement confirms the Schedule 13G is filed on behalf of both reporting persons.
ASP Isotopes Inc. reported leadership changes tied to its closing of the previously announced acquisition of Renergen Limited on January 6, 2026. Renergen’s Chief Executive Officer, Stefano Marani, has been appointed President, Electronics and Space of ASP Isotopes, and Renergen’s Chief Operating Officer, Nick Mitchell, has been appointed Co-Chief Operating Officer of ASP Isotopes.
The company expects to enter into employment agreements providing Mr. Marani a base salary of $550,000 per year and Mr. Mitchell $400,000 per year, each with a target annual discretionary bonus equal to 50% of base salary, payable in a mix of cash and common stock. Each executive has been approved for a grant of 700,000 shares of common stock, vesting in eight equal installments over four years, with 87,500 shares vesting on each six‑month anniversary of employment, subject to continued service.
The stock awards are being made under ASP Isotopes’ inducement equity incentive plans in line with Nasdaq Listing Rule 5635(c)(4), and both executives will also be eligible for annual equity awards under the company’s 2022 Equity Incentive Plan. Due to prior transactions between ASP Isotopes and Renergen, including a $30 million bridge loan agreement, the company notes that Mr. Marani and Mr. Mitchell may be deemed to have a direct or indirect material interest in such dealings for related‑party disclosure purposes.